Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

被引：4
|
作者：
Wang, Chen [1 ]
McGraw, Kathy L. [2 ]
McLemore, Amy F. [2 ]
Komrokji, Rami [2 ]
Basiorka, Ashley A. [2 ]
Al Ali, Najla [2 ]
Lancet, Jeffrey E. [2 ]
Padron, Eric [2 ]
Kosmider, Olivier [3 ]
Fontenay, Michaela [3 ]
Fenaux, Pierre [4 ]
List, Alan F. [2 ]
Sallman, David A. [2 ]
机构：
[1] Univ S Florida, Dept Internal Med, Morsani Coll Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Ctr Univ Paris, Serv Hematol Biol, Hop Cochin, Assistance Publ Hop Paris, Paris, France
[4] Hop St Louis, Grp Francophone Myelodysplasies, Paris, France
来源：
HAEMATOLOGICA | 2022年 / 107卷 / 03期
关键词：
MECHANISM;
D O I：
10.3324/haematol.2021.278855
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [41] Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
    A F List
    J M Bennett
    M A Sekeres
    B Skikne
    T Fu
    J M Shammo
    S D Nimer
    R D Knight
    A Giagounidis
    Leukemia, 2015, 29 : 2452 - 2452
  • [42] Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes
    Chesnais, Virginie
    Arcangeli, Marie-Laure
    Delette, Caroline
    Rousseau, Alice
    Guermouche, Helene
    Lefevre, Carine
    Bondu, Sabrina
    Diop, M'boyba
    Cheok, Meyling
    Chapuis, Nicolas
    Legros, Laurence
    Raynaud, Sophie
    Willems, Lise
    Bouscary, Didier
    Lauret, Evelyne
    Bernard, Olivier A.
    Kosmider, Olivier
    Pflumio, Francoise
    Fontenay, Michaela
    BLOOD, 2017, 129 (04) : 484 - 496
  • [43] A Calcium-Dependent Pathway Determines Response to Lenalidomide in Del(5q) Myelodysplastic Syndromes
    Fang, Jing
    Liu, Xiaona
    Bolanos, Lyndsey
    Barker, Brenden
    Rigolino, Carmela
    Cortelezzi, Agostino
    Oliva, Esther Natalie
    MacBeth, Kyle J.
    Komurov, Kakajan
    Starczynowski, Daniel T.
    BLOOD, 2014, 124 (21)
  • [44] Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide
    Lode, Laurence
    Menard, Audrey
    Flet, Laurent
    Richebourg, Steven
    Loirat, Marion
    Eveillard, Marion
    Le Bris, Yannick
    Godon, Catherine
    Theisen, Olivier
    Gagez, Anne-Laure
    Cartron, Guillaume
    Commes-Maerten, Therese
    Villemagne, Bruno
    Luycx, Odile
    Godmer, Pascal
    Pellat-Deceunynck, Catherine
    Soussi, Thierry
    Bene, Marie C.
    Delaunay, Jacques
    Peterlin, Pierre
    HAEMATOLOGICA, 2018, 103 (04) : E143 - E146
  • [45] Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents
    Sibon, David
    Cannas, Giovanna
    Baracco, Fiorenza
    Prebet, Thomas
    Vey, Norbert
    Banos, Anne
    Besson, Caroline
    Corm, Selim
    Blanc, Michel
    Slama, Bohrane
    Perrier, Herve
    Fenaux, Pierre
    Wattel, Eric
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (05) : 619 - 625
  • [46] RECURRENT MUTATIONS AS WELL AS CLONAL EVOLUTION ARE COMMON IN PATIENTS WITH LOWER-RISK MDS AND DEL(5Q) TREATED WITH LENALIDOMIDE
    Scharenberg, C.
    Karimi, M.
    Jansson, M.
    Walldin, G.
    Woll, P.
    Jacobsen, S. E.
    Hellstrom-Lindberg, E.
    LEUKEMIA RESEARCH, 2015, 39 : S84 - S84
  • [47] Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study
    Matsuda, Akira
    Taniwaki, Masafumi
    Jinnai, Itsuro
    Harada, Hironori
    Watanabe, Mitsumasa
    Suzuki, Kenshi
    Yanagita, Soshi
    Suzuki, Takahiro
    Yoshida, Yataro
    Kimura, Akiro
    Tsudo, Mitsuru
    Tohyama, Kaoru
    Takatoku, Masaaki
    Ozawa, Keiya
    LEUKEMIA RESEARCH, 2012, 36 (05) : 575 - 580
  • [48] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Butrym, Aleksandra
    Lech-Maranda, Ewa
    Patkowska, Elzbieta
    Kumiega, Beata
    Bieniaszewska, Maria
    Mital, Andrzej
    Madry, Krzysztof
    Torosian, Tigran
    Wichary, Ryszard
    Rybka, Justyna
    Warzocha, Krzysztof
    Mazur, Grzegorz
    BMC CANCER, 2015, 15
  • [49] Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q)
    Aleksandra Butrym
    Ewa Lech-Maranda
    Elżbieta Patkowska
    Beata Kumiega
    Maria Bieniaszewska
    Andrzej Mital
    Krzysztof Madry
    Tigran Torosian
    Ryszard Wichary
    Justyna Rybka
    Krzysztof Warzocha
    Grzegorz Mazur
    BMC Cancer, 15
  • [50] Prediction of Response to Treatment with Lenalidomide in Patients with Non-Del 5q Myelodysplastic Syndrome by Gene Expression Profiling Remains Difficult.
    Hofmann, Wolf-Karsten
    Nolte, Florian
    Benlasfer, Ouidad
    Thiel, Eckhard
    Ehninger, Gerhard
    Platzbecker, Uwe
    BLOOD, 2009, 114 (22) : 1088 - 1088
12345